NCT04389229 (OVSTAR) is a Phase 1, PHASE2 clinical trial of cyclophosphamide in Ovarian Cancer Metastatic, sponsored by Immetacyte Ltd.

Who is sponsoring NCT04389229?

NCT04389229 is sponsored by Immetacyte Ltd.

What drugs are being tested in NCT04389229?

Interventions in NCT04389229: cyclophosphamide, fludarabine, IL-2 (Proleukin), Unmodified Tumour Infiltrating Lymphocytes (UTIL-01), Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01).

What condition does NCT04389229 study?

NCT04389229 studies Ovarian Cancer Metastatic.

Is NCT04389229 still recruiting?

NCT04389229 is currently withdrawn. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT04389229: OVSTAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Withdrawn Phase 1, PHASE2 Last updated 16 December 2020

What this trial tests

Phase 1, PHASE2 trial testing cyclophosphamide in Ovarian Cancer Metastatic. Withdrawn.

Timeline

1 July 2020

Primary endpoint
31 March 2023

31 July 2025

Quick facts

Lead sponsor	Immetacyte Ltd
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	1 July 2020
Primary completion	31 March 2023
Estimated completion	31 July 2025
Sites	2 locations across United Kingdom

Drugs / interventions tested

cyclophosphamide (cyclophosphamide) — full drug profile →
fludarabine (FLUDARABINE) — full drug profile →
IL-2 (Proleukin) — full drug profile →
Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)
Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)

Conditions studied

Ovarian Cancer Metastatic — all drugs for Ovarian Cancer Metastatic →

Sponsor

Immetacyte Ltd — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer. The purpose of this phase I/II study is to evaluate the feasibility and safety of both standard unmodified TIL (UTIL-01) and TIL engineered to express the co-stimulatory receptor CoStAR (CoTIL-01) in platinum resistant ovarian cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adoptive T cell therapy for ovarian cancer.
Gitto SB, Ihewulezi CJN, Powell DJ. · · 2024 · cited 16× · PMID 38603955 · DOI 10.1016/j.ygyno.2024.04.001

Verify or expand the search:

Other trials of cyclophosphamide

Trials testing the same drug.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT06865664 — FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma · Phase 1 · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06744504 — Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 · Phase 3 · recruiting
NCT06361329 — Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL · Phase 3 · recruiting

Other recruiting trials for Ovarian Cancer Metastatic

Currently open trials in the same condition.

NCT07311577 — Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD- · Phase 2 · recruiting
NCT07009743 — O-RADS MRI System on Early Detection of Ovarian Cancer · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04389229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immetacyte Ltd
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04389229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing